A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Cancer Survivors Face High Rates of Housing Insecurity February 5, 2022 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion February 19, 2025 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 Load more HOT NEWS FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... Answers to Your Questions About Sunscreen Ingredients The Healing Power of Being Outdoors for People With Cancer
